CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $10M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 11.75: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
437.26MUSDvs all stocks (USD)
Revenue (TTM)
10.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-39.99%vs all stocks
Market Capitalization
437.26MUSDvs all stocks (USD)
Enterprise Value
234.91MUSDvs all stocks (USD)
Forward P/E
-3.75xvs Biotechnology peers
Price to Sales (TTM)
43.73xvs Biotechnology peers
Price to Book (MRQ)
1.44xvs Biotechnology peers
Enterprise to Revenue
23.49xvs Biotechnology peers
Enterprise to EBITDA
-2.65xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-899.93%vs Biotechnology peers
Return on Assets (TTM)
-29.72%vs Biotechnology peers
Return on Equity (TTM)
-44.95%vs Biotechnology peers
Revenue (TTM)
10.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.7060USDUpdated Jul 18, 2026Gross Profit (TTM)
10.00MUSDvs all stocks (USD)
EBITDA (TTM)
-88.63MUSDvs all stocks (USD)
Net Income (TTM)
-75.99MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-80.05MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-57.53MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
13.00MUSDFY2025 · Dec 31, 2025Operating Income
-81.07MUSDvs all stocks (USD)
Pre-tax Income
-68.87MUSDFY2025 · Dec 31, 2025Net Income
-68.87MUSDFY2025 · Dec 31, 2025EBIT
-81.07MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-88.61MUSDFY2025 · Dec 31, 2025Research & Development
74.04MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
20.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.32MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-68.87MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
-67.96MUSDFY2025 · Dec 31, 2025Free Cash Flow
-68.20MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.39M of depreciation against 235K of capital expenditure, and its own free-cash-flow line reads -76.68M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
45.48MUSDFY2025 · Dec 31, 2025Interest Paid
7.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-68.87MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.39MUSDFY2025 · Dec 31, 2025Stock-based Compensation
5.86MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.77MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-837.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.73MUSDFY2025 · Dec 31, 2025Capital Expenditures
-235.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-199.17MUSDFY2025 · Dec 31, 2025Sale of Investments
84.10MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-115.31MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-373.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.38MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
63.47MUSDFY2025 · Dec 31, 2025Shares Outstanding
36.02MSharesUpdated Jul 18, 2026Float Shares
19.98MSharesUpdated Jul 18, 2026Shares Short
4.78MSharesUpdated Jul 18, 2026Short Ratio
4.35daysvs all stocks
Short % of Shares Outstanding
19.71%vs all stocks
% Held by Insiders
3.18%vs all stocks
% Held by Institutions
116.20%vs all stocks
Total Cash (MRQ)
211.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.87USDUpdated Jul 18, 2026Total Debt (MRQ)
9.11MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0299xvs Biotechnology peers
Current Ratio (MRQ)
20.36xvs Biotechnology peers
Book Value per Share (MRQ)
8.46USDUpdated Jul 18, 2026Total Assets
224.95MUSDvs all stocks (USD)
Total Current Assets
153.48MUSDFY2025 · Dec 31, 2025Total Liabilities
19.38MUSDFY2025 · Dec 31, 2025Total Non-current Assets
71.47MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
17.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
44.06MUSDFY2025 · Dec 31, 2025Other Short-term Investments
105.14MUSDFY2025 · Dec 31, 2025Accounts Payable
7.76MUSDFY2025 · Dec 31, 2025Short-term Debt
242.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
364.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.47MUSDFY2025 · Dec 31, 2025Common Stock (Book)
3.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-221.09MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
205.57MUSDvs all stocks (USD)
52-Week Low
11.50USDUpdated Jul 18, 202652-Week High
33.20USDUpdated Jul 18, 202652-Week Change
-39.99%vs all stocks
50-Day MA
19.52USDUpdated Jul 18, 2026200-Day MA
21.30USDUpdated Jul 18, 2026Avg 10-Day Volume
943.58KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.15MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.11USDUpdated Jul 18, 2026Other Income / Expense
8.88MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 11.75: safe zoneNotable
Altman Z-Score: 11.75
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $10M, lower than 95% of all stocks globallySignificant
Revenue (USD): 10,000,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Benitec Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gujarat Themis Biosyn Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Synergy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Puma Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Baotou Dongbao Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Canopy Growth Corporation
Tier 1ProductionApproval-Gated PipelineFlowRule
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated